-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although chemotherapy immunotherapy has been widely used in the treatment of high-risk neuroblastoma (HRNB) in children, the response time, duration, and progression after treatment with irinotecan/temozolomide/denutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) are unknown
This retrospective study enrolled patients younger than 30 years of age who had previously received ≥ 1 course of I/T/DIN/GM-CB-CF for relapsed or refractory conditions
A total of 146 patients were included, and MYCN amplification
Patients were treated with a median course of 4.
Overall, approximately half of patients with recurrent high-risk neuroblastoma who received I/T/DIN/GM-CSF received objective remission
Original Source:
Benjamin J.